



February 28, 2011

Peregrine Announces Four Abstracts Accepted for Presentation at AACR Annual Meeting

TUSTIN, CA -- (MARKET WIRE) -- 02/28/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that data from four studies investigating the company's lead phosphatidylserine (PS)-targeting clinical candidate bavituximab and other PS-targeting antibodies have been accepted for poster presentation at the 102nd Annual Meeting of the American Association for Cancer Research (AACR) to be held in Orlando, Florida, April 2-6, 2011.

Abstracts Accepted at AACR:

Title: [Targeting Phosphatidylserine to Improve Androgen Deprivation Therapy of Prostate Cancer](#)

Authors: Yi Yin and Philip E. Thorpe

Presentation Time: Sunday, April 3, 2011, 1:00 - 5:00 PM ET

Location: Exhibit Hall A4-C, Poster Section 26

Title: [Phosphatidylserine-Targeting Antibody Induces Differentiation of Myeloid-Derived Suppressor Cells into M1-Like Macrophages](#)

Authors: Xianming Huang, Dan Ye, and Philip E. Thorpe

Presentation Time: Tuesday, April 5, 2011, 8:00 AM -12:00 PM ET

Location: Exhibit Hall A4-C, Poster Section 31

Title: [Phosphatidylserine-Targeting Antibody Combined with Sorafenib has Strong Anti-Tumor Activity against Human Hepatocellular Carcinomas in Mice](#)

Authors: Xiaoyun Cheng and Philip E. Thorpe

Presentation Time: Tuesday, April 5, 2011, 8:00 AM -12:00 PM ET

Location: Exhibit Hall A4-C, Poster Section 30

Title: [Monitoring Tumor Response to Chemotherapy by In Vivo Real-Time Imaging of Phosphatidylserine Targeting Antibodies](#)

Authors: Jian Gong, Linda Him, Christopher Hughes, and Bruce Freimark

Presentation Time: Wednesday, April 6, 2011, 8:00 AM -12:00 PM ET

Location: Exhibit Hall A4-C, Poster Section 5

For additional information on the 102nd Annual Meeting of the AACR, please visit:

<http://www.aacr.org/home/scientists/meetings--workshops/aacr-102nd-annual-meeting-2011.aspx>

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and hepatitis C virus infection with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

[Add to Digg](#) [Bookmark with del.icio.us](#) [Add to Newsvine](#)

Peregrine Contact:

Amy Figueroa

Peregrine Pharmaceuticals

(800) 987-8256

info@peregrineinc.com

Source: Peregrine Pharmaceuticals

News Provided by Acquire Media